News >

Memory-Related Genes May Overcome Resistance to CAR T-Cell Therapy in CLL

Jason Harris
Published: Thursday, May 03, 2018

J. Joseph Melenhorst, PhD

J. Joseph Melenhorst, PhD
Results from a recent study may show why some patients with chronic lymphocytic leukemia (CLL) are resistant to tisagenlecleucel (Kymriah), while potentially offering a pathway to enhance patient response.

The study, led by senior author J. Joseph Melenhorst, PhD, and first author Joseph A. Fraietta, PhD, both faculty at the University of Pennsylvania, Department of Pathology and Laboratory Medicine, at the Center for Cellular Immunotherapies, demonstrated that patients with healthier, “early memory” cytotoxic T cells were far more likely to have a complete or partial response to treatment. In a validation study, this early memory T cell signature predicted patients who would experience CR with 100% accuracy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x